• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Jublpharma Share Price

    Jubilant Pharmova Share PriceJubilant Pharmova

    Mid Cap 4.9k Result
    ₹432.6
    14.8 (3.54%)
    • Advice
    • Hold
    As on 28 November, 2023 | 22:23 BSE: 530019 NSE: JUBLPHARMAISIN: INE700A01033

    Jubilant Pharmova Performance

    Day Range

    • Low 409.4
    • High 436
    432.6

    52 Week Range

    • Low 268.9
    • High 485.1
    432.6
    • Open Price419.85
    • Previous Close420.75
    • Volume417372

    Start SIP in Jubilant Pharmova

    Start SIP

    Jubilant Pharmova Share Price

    • Over 1 Month 8.9%
    • Over 3 Month -7.35%
    • Over 6 Month 19.21%
    • Over 1 Year 13.34%

    Jubilant Pharmova Key Statistics

    P/E Ratio -154.5
    PEG Ratio 1.2
    Market Cap Cr 6,891
    Price to Book Ratio 1.3
    EPS 3.1
    Dividend 1.2
    Relative Strength Index 60.3
    Money Flow Index 72.12
    MACD Signal 3.88
    Average True Range 16.98

    Jubilant Pharmova Investment Rating

    • Master Rating:

    • Jubilant Pharmova has an operating revenue of Rs. 6,497.71 Cr. on a trailing 12-month basis. An annual revenue growth of 3% is not great, Pre-tax margin of 0% needs improvement, ROE of -1% is poor and needs improvement. The company has a debt to equity of 58%, which is bit higher. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 12% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 13% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 43 which is a POOR score indicating inconsistency in earnings, a RS Rating of 38 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 78 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Jubilant Pharmova Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 18620418918321520029
    Operating Expenses Qtr Cr 18621319818521620930
    Operating Profit Qtr Cr 142-27-4-2
    Depreciation Qtr Cr 121111121192
    Interest Qtr Cr 7666438
    Tax Qtr Cr 1030-56-1-1
    Net Profit Qtr Cr 02-31-692-5-3
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 948214
    Operating Expenses Annual Cr 80795
    Operating Profit Annual in Cr 3-7
    Depreciation Cr 436
    Interest Annual Cr 1931
    Tax Annual Cr 294
    Net Profit Annual Cr 5079
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr -65-4
    Cash from Investing Activity Annual Cr 3193
    Cash from Financing Annual Activity Cr 23-107
    Net Cash Flow Annual Cr -12-18
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 2,4151,282
    Fixed Assets Annual Cr 734124
    Total Non Current Assets Annual Cr 2,4301,782
    Total Current Assets Annual Cr 57948
    Total Assets Annual Cr 3,0081,829
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 15280
    ROE Annual % 26
    ROCE Annual % 46
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 17136
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 1,6671,5671,6611,5531,5851,4401,514
    Operating Expenses Qtr Cr 1,4391,4171,4591,4071,3811,2591,280
    Operating Profit Qtr Cr 242170219146219192234
    Depreciation Qtr Cr 9790271949495101
    Interest Qtr Cr 66625651424040
    Tax Qtr Cr 36191425312247
    Net Profit Qtr Cr 636-98-1654760
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 6,3206,141
    Operating Expenses Annual Cr 5,5054,974
    Operating Profit Annual in Cr 7761,156
    Depreciation Cr 554382
    Interest Annual Cr 188145
    Tax Annual Cr 93217
    Net Profit Annual Cr -61414
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 661838
    Cash from Investing Activity Annual Cr -544-380
    Cash from Financing Annual Activity Cr -157-33
    Net Cash Flow Annual Cr -40425
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 5,3995,319
    Fixed Assets Annual Cr 4,3163,717
    Total Non Current Assets Annual Cr 7,3946,482
    Total Current Assets Annual Cr 3,7623,509
    Total Assets Annual Cr 11,1579,991
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 339334
    ROE Annual % -18
    ROCE Annual % 39
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1319
    Invest in Jubilant Pharmova

    Jubilant Pharmova Technicals

    EMA & SMA

    Current Price
    ₹432.6
    14.8 (3.54%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹414.85
    • 50 Day
    • ₹412.37
    • 100 Day
    • ₹405.83
    • 200 Day
    • ₹393.74
    • 20 Day
    • ₹409.68
    • 50 Day
    • ₹412.02
    • 100 Day
    • ₹414.53
    • 200 Day
    • ₹371.85

    Jubilant Pharmova Resistance and Support

    PIVOT
    ₹426.
    Resistance
    First Resistance ₹442.6
    Second Resistance ₹452.6
    Third Resistance ₹469.2
    RSI 60.3
    MFI 72.12
    MACD Single Line 3.88
    MACD 6.42
    Support
    First Resistance ₹416
    Second Resistance ₹399.4
    Third Resistance ₹389.4

    Jubilant Pharmova Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 462,621 24,662,326 53.31
    Week 275,295 16,649,811 60.48
    1 Month 451,144 21,388,751 47.41
    6 Month 354,802 13,237,665 37.31

    Jubilant Pharmova Result Highlights

    Jubilant Pharmova Synopsis

    NSE-Medical-Diversified

    Jubilant Pharmova is involved in the business activities of Manufacture of basic chemicals. Company’s Total Operating Revenue is Rs. 810.12 Cr. and Equity Capital is Rs. 15.93 Cr. for the Year ended 31/03/2023. Jubilant Pharmova Ltd. is a Public Limited Listed company incorporated on 21/06/1978 and has its registered office in the State of Uttar Pradesh, India. Company’s Corporate Identification Number(CIN) is L24116UP1978PLC004624 and registration number is 004624.
    Market Cap 6,839
    Sales 786
    Shares in Float 7.80
    No of funds 152
    Yield 1.2
    Book Value 2.76
    U/D Vol ratio 1.5
    LTDebt / Equity 7
    Alpha 0.02
    Beta 1.29

    Jubilant Pharmova

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 50.68%50.68%50.68%50.68%
    Mutual Funds 0.42%0.41%0.4%0.4%
    Foreign Portfolio Investors 23.2%23.2%23.22%23.38%
    Financial Institutions/ Banks
    Individual Investors 18.24%18.25%18.69%18.68%
    Others 7.46%7.46%7.01%6.86%

    Jubilant Pharmova Management

    Name Designation
    Mr. Shyam S Bhartia Chairman
    Mr. Hari S Bhartia Co-Chairman
    Mr. Priyavrat Bhartia Managing Director
    Mr. Arjun Shanker Bhartia Joint Managing Director
    Mr. Arvind Chokhany WholeTime Director & Group CFO
    Mr. R Kumar Whole Time Director
    Mr. Vivek Mehra Independent Director
    Mr. Sushil Kumar Roongta Independent Director
    Mr. Arun Seth Independent Director
    Ms. Sudha Pillai Independent Director
    Dr. Ashok Misra Independent Director
    Mr. S Sridhar Independent Director
    Mr. Shirish G Belapure Independent Director

    Jubilant Pharmova Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Jubilant Pharmova Corporate Action

    Date Purpose Remarks
    2023-10-27 Quarterly Results
    2023-07-19 Quarterly Results
    2023-05-29 Audited Results & Final Dividend
    2023-02-03 Quarterly Results
    2022-10-21 Quarterly Results
    Date Purpose Remarks
    2023-08-10 FINAL Rs.5.00 per share(500%)Final Dividend
    2022-08-12 FINAL Rs.5.00 per share(500%)Final Dividend
    2021-08-06 FINAL Rs.5.00 per share(500%)Final Dividend

    Jubilant Pharmova MF Shareholding

    Name Amount(cr)
    Nippon India Pharma Fund - Growth 5539
    Nippon India Nifty Smallcap 250 Index Fund Reg Gr 719
    Motilal Oswal Nifty 500 Fund Regular Growth 548
    Motilal Oswal Nifty Smallcap 250 Index Fund Regular Growth 453
    SBI Nifty Smallcap 250 Index Fund Regular Growth 332

    Jubilant Pharmova FAQs

    What is Share Price of Jubilant Pharmova ?

    Jubilant Pharmova share price is ₹432 As on 28 November, 2023 | 22:09

    What is the Market Cap of Jubilant Pharmova ?

    The Market Cap of Jubilant Pharmova is ₹6890.5 Cr As on 28 November, 2023 | 22:09

    What is the P/E ratio of Jubilant Pharmova ?

    The P/E ratio of Jubilant Pharmova is -154.5 As on 28 November, 2023 | 22:09

    What is the PB ratio of Jubilant Pharmova ?

    The PB ratio of Jubilant Pharmova is 1.3 As on 28 November, 2023 | 22:09

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.